ValueAct’s Big Year Continues With Third-Quarter Gains
The sometime-activist is on pace to post its best results in six years.
Stephen TaubOctober 7, 2019
An Olympus Medical Systems LED endoscope.
(Tomohiro Ohsumi/Bloomberg)
Jeff Ubben’s ValueAct Capital extended its gains in the third quarter in both of its main funds after enjoying a strong first half.The ValueAct Master Fund rose 1.3 percent in the September period, boosting its gain for the year to 22.2 percent, according to an
To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.